T0	Participants 52 79	superficial bladder cancer.
T1	Participants 320 419	in patients with primary or recurrent superficial bladder tumors, including carcinoma in situ (CIS)
T2	Participants 770 771	.
T3	Participants 772 922	Reported are the incidence of side effects in 165 patients and the recurrence rate of tumors in 308 patients after a follow-up period of twelve months